GFH276

PreclinicalSmall molecule

GGenfleet Therapeutics (Shanghai) Inc.

GFH276 is one of 8 small molecule programs targeting Advanced Solid Tumors Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid Tumors CancerNot yet recruiting

Advanced Solid Tumors CancerPreclinical

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Advanced Solid Tumors Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Preclinical

1 2

Gemzar

Johnson & Johnson

Preclinical

1 3

Camptosar

Pfizer

Preclinical

1 4

Eloxatin

Teva

Preclinical

1 5

Erbitux

IImclone

Preclinical

1 6

Adrucil

EElorac, Inc.

Preclinical

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

GFH276

GGenfleet Therapeutics (Shanghai) Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Not yet recruiting

Advanced Solid Tumors

NCT07198321

Q3 2028

PreclinicalNot yet recruiting

Advanced Solid Tumors Cancer

NCT07678593

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT07198321·450 enrolled

Advanced Solid Tumors Cancer1 trial

A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Preclinical·NCT07678593·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GFH276. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GFH276 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GFH276. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genfleet Therapeutics (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGenfleet Therapeutics (Shanghai) Inc.

GFH276

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

Advanced Solid Tumors Cancer1 trial

References

Drug Info

Quick Facts

Related News